country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Referencia número: HY-P9981

Copy Link Print Information

Biologically Validated

Tafasitamab

Name: Tafasitamab
Brand: MedChemExpress
SKU: HY-P9981
Price: 290.00 USD
Availability: InStock
Rating: 5 (2 reviews)

(Synonyms: XmAb5574; MOR00208; Tafasitamab-cxix; MOR-208)

2 Cited Publications

Revisión del cliente

Based on 2 publication(s) in Google Scholar

Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.71%
No. CAS: 1422527-84-1
Peso molecular:147.42 kDa

Almacenamiento:

Please store the product under the recommended conditions in the Certificate of Analysis.

Tafasitamab Chemical Structure

No. CAS: 1422527-84-1

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Ensayo clínico
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Aplicación
- Verified Bioactivity
Chemical Information
Publications (2)
Pureza y Documentación
Referencias
Calculators
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19^[1]^[2].

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

CD19

In Vitro

Tafasitamab (XmAb5574) induces cytotoxicity against Mino and Jeko (MCL) cell lines in an E/T ratio-dependent manner. Tafasitamab (XmAb5574) increases ADCP and antiproliferative activity. Tafasitamab (XmAb5574) enhances antiproliferative apoptotic activity due to caspase-induced apoptosis^[1]^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

NHL cell lines and primary CLL and MCL cells by γδ T cells
Concentration:
Incubation Time:

2 h
Result:

Induced killing of NHL cell lines and primary CLL and MCL cells by γδ T cells.

Cell Proliferation Assay^[2]

Cell Line:

SU-DHL-6 cells
Concentration:
Incubation Time:

72 h
Result:

Showed potent antiproliferative effects on tumor cell.

Apoptosis Analysis^[2]

Cell Line:

SU-DHL-6 cells
Concentration:

0-4 ng/mL
Incubation Time:

48 h
Result:

Showed potent antiproliferative effects due to caspase-induced apoptosis

In Vivo

Tafasitamab (SC, once on Day 1, 2.5 μg/kg) inhibits lymphoma growth in disseminated BL mouse xenograft tumor models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Disseminated Raji model^[1].
Dosage:

2.5 μg/kg
Administration:

Tafasitamab (SC, once on Day 1, 2.5 μg/kg)
Result:

Showed antitumor activity in disseminated Raji model.

Animal Model:

Disseminated Ramos model^[1].
Dosage:

10 mg/kg
Administration:

Tafasitamab (IV, on Days 3, 6, 10, 13, 17, and 20 at a dose of 10 mg/kg)
Result:

Showed antitumor activity in disseminated Ramos model.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

930 [NCBI]

Accession

P15391

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

IgG1-G2-kappa

Aplicación

ELISA, FACS, Functional assay

Verified Bioactivity

Immobilized CD19 Protein, Human (HEK293, His, HY-P74330) can bind Tafasitamab. The EC₅₀ for this effect is 29.1 ng/mL.
Tafasitamab has a significant ADCP effect on Raji cells in a dose-dependent manner.The EC₅₀ for this effect is 95.42 and 117.87 ng/mL.

Chemical Information

No. CAS 1422527-84-1
Appearance Liquid
Peso molecular 147.42 kDa
Color Colorless to light yellow
SMILES

[Tafasitamab]
Synonyms

XmAb5574; MOR00208; Tafasitamab-cxix; MOR-208
Envío

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (2)

All

Sort by:

Journal Impact Factor

Cytotherapy

2026 May 16.
Clin Chem Lab Med

Tafasitamab interference in immunofixation electrophoresis. [Abstract]

2025 Sep 15. PMID: 40965972

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (262 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Referencias

[1]. Jung Hyun Her, et al. Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunol Immunother. 2022 Mar 29. [Content Brief]

[2]. Holly M Horton, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res [Content Brief]

Calculators

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Tafasitamab

2 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Obtener un presupuesto En stock

Other size

Obtener un presupuesto

Amount: USD 0.00

Actividad biológica
- Descripciòn
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Ensayo clínico
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Aplicación
- Biological Activity
Chemical Information
Publications (2)
Pureza y Documentación
Referencias

1/16

IgG1-G2-kappa
1/16

Immobilized CD19 Protein, Human (HEK293, His, HY-P74330) can bind Tafasitamab. The EC₅₀ for this effect is 29.1 ng/mL.
1/16

Tafasitamab has a significant ADCP effect on Raji cells in a dose-dependent manner.The EC₅₀ for this effect is 95.42 and 117.87 ng/mL.
1/16

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Tafasitamab

Publications Citing Use of MedChemExpress (MCE) Tafasitamab